The Complement Lectin Pathway After Cardiac Arrest
The Complement Lectin Pathway in Patients Resuscitated After Cardiac Arrest
This study includes comatose survivors of out-of-hospital cardiac arrest treated with 24 hours or 48 hours of targeted temperature management.
The overall aim is to evaluate the importance of plasma complement protein concentrations in patients resuscitated after out-of-hospital cardiac arrest and treated with 24 hours or 48 hours of targeted temperature management.
The specific aim is to evaluate:
- the concentration of plasma lectin pathway proteins the first, second and third day after cardiac arrest
- the relation between concentration of plasma lectin pathway proteins and mortality
- if prolonged targeted temperature management influences the concentration of plasma lectin pathway proteins
This study is a sub-study to the trial entitled: "Time-differentiated targeted temperature management (TTH48) (ClinicalTrials.gov Identifier: NCT01689077)"
The following Complement Lectin Pathway proteins will be measured: Mannan-Binding-Lectin, M-ficolin, H-ficolin, CL-L1, MASP-1, MASP-2, MASP-3, MAp19 and MAp44.
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Aarhus、デンマーク、8000
- Department of Biomedicine, Aarhus University
-
Aarhus、デンマーク、8200
- Department of Anesthesiology and Intensive Care, Aarhus University Hospital
-
Aarhus、デンマーク、8200
- Department of Clinical Biochemistry, Aarhus University Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Out-of-Hospital Cardiac Arrest of presumed cardiac cause
- Return of spontaneous circulation (ROSC)
- Glasgow Coma Score < 8
- Age > 18 years and < 80 years
Exclusion Criteria:
- > 60 minutes from the circulatory collapse to ROSC
- Time interval > 4 hours from cardiac arrest to initiation of targeted temperature management
- Terminal illness
- Coagulation disorder
- Unwitnessed asystolia
- Cerebral performance category 3-4 before the cardiac arrest
- Severe persistent cardiogenic shock
- Pregnancy
- Persistent cardiogenic shock (systolic bloodpressure < 80 despite inotropic treatment)
- New apoplexy or cerebral hemorrhage
- Lack of consent from the relatives
- Lack of consent from the general practitioner
- Lack of consent from the patient
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
アクティブコンパレータ:24 hour of targeted temperature management
Patients resuscitated after cardiac arrest and treated with 24 hours of targeted temperature management (33 degree Celsius)
|
|
実験的:48 hour of targeted temperature management
Patients resuscitated after cardiac arrest and treated with 48 hours of targeted temperature management (33 degree Celsius)
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
MASP-2 concentration in plasma
時間枠:48 hours
|
48 hours
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
MASP-2 concentration in plasma
時間枠:24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
MASP-2 concentration in plasma
時間枠:24 hours, 48 hours, 72 hours
|
MASP-2 concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
MASP-2 concentration in plasma
時間枠:24 hours to 72 hours
|
24 hours to 72 hours
|
|
MASP-1 concentration in plasma
時間枠:24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
MASP-1 concentration in plasma
時間枠:24 hours to 72 hours
|
24 hours to 72 hours
|
|
MASP-1 concentration in plasma
時間枠:24 hours, 48 hours, 72 hours
|
MASP-1 concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
MASP-3 concentration in plasma
時間枠:24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
MASP-3 concentration in plasma
時間枠:24 hours to 72 hours
|
24 hours to 72 hours
|
|
MASP-3 concentration in plasma
時間枠:24 hours, 48 hours, 72 hours
|
MASP-3 concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
Mannan-Binding-Lectin concentration in plasma
時間枠:24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
Mannan-Binding-Lectin concentration in plasma
時間枠:24 hours to 72 hours
|
24 hours to 72 hours
|
|
Mannan-Binding-Lectin concentration in plasma
時間枠:24 hours, 48 hours, 72 hours
|
Mannan-Binding-Lectin concentration in plasma compared to 30-day mortality
|
24 hours, 48 hours, 72 hours
|
MAp44 concentration in plasma
時間枠:24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
Map44 concentration in plasma
時間枠:24 hours to 72 hours
|
24 hours to 72 hours
|
|
MAp44 concentration in plasma
時間枠:24 hours, 48 hours, 72 hours
|
MAp44 concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
MAp19 concentration in plasma
時間枠:24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
MAp19 concentration in plasma
時間枠:24 hours to 72 hours
|
24 hours to 72 hours
|
|
MAp19 concentration in plasma
時間枠:24 hours, 48 hours, 72 hours
|
MAp19 concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
H-ficolin concentration in plasma
時間枠:24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
H-ficolin concentration in plasma
時間枠:24 hours to 72 hours
|
24 hours to 72 hours
|
|
H-ficolin concentration in plasma
時間枠:24 hours, 48 hours, 72 hours
|
H-ficolin concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
M-ficolin concentration in plasma
時間枠:24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
M-ficolin concentration in plasma
時間枠:24 hours to 72 hours
|
24 hours to 72 hours
|
|
M-ficolin concentration in plasma
時間枠:24 hours, 48 hours, 72 hours
|
M-ficolin concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
CL-L1 concentration in plasma
時間枠:24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
CL-L1 concentration in plasma
時間枠:24 hours to 72 hours
|
24 hours to 72 hours
|
|
CL-L1 concentration in plasma
時間枠:24 hours, 48 hours, 72 hours
|
CL-L1 concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。